佛慈制药：公司中成药制造板块2025年上半年毛利率为39.93%

Core Viewpoint - The company reported an increase in gross margin for its traditional Chinese medicine manufacturing segment, attributed to lower raw material costs and improved operational efficiency [1] Group 1: Financial Performance - The gross margin for the traditional Chinese medicine manufacturing segment in the first half of 2025 is 39.93%, an increase of 5.32% compared to the same period last year [1] - The decrease in the price of Chinese medicinal materials has contributed to a reduction in production costs [1] Group 2: Strategic Initiatives - The company is focusing on expanding its external market reach and enhancing internal cost reduction and efficiency measures [1] - Future plans include continuous market development and further cost reduction to improve overall profitability and product gross margin [1]